| Literature DB >> 33260150 |
Clara Sciorati1, Riccardo Gamberale1, Antonella Monno1, Lorena Citterio2, Chiara Lanzani2, Rebecca De Lorenzo1,3, Giuseppe A Ramirez1,3, Antonio Esposito3,4, Paolo Manunta2,3, Angelo A Manfredi1,3, Patrizia Rovere-Querini1,3.
Abstract
Sarcopenia is a hallmark of aging. Inflammation due to increased generation of cytokines such as TNFα, IL-1β and IL-6 has been implicated in the pathogenesis of sarcopenia. In skeletal muscle of C57BL/6 mice from 12 until 28 months of age, we observed a progressive reduction of myofiber cross sectional area, loss of type II fibers and infiltration by inflammatory cells. Muscle strength decreased in parallel. Pharmacological TNFα blockade by weekly subcutaneous injection of Etanercept from 16 to 28 months of age prevented atrophy and loss of type II fibers, with significant improvements in muscle function and mice lifespan. The effects on leukocyte recruitment were limited. These results provide a proof of principle that endogenous TNFα is sufficient to cause sarcopenia and to reduce animal survival, and open a novel perspective on novel potential pharmacological treatment strategies based on TNFα blockade to prevent the noxious events associated with aging.Entities:
Keywords: TNF alpha; aging; inflammation; pharmacological intervention; sarcopenia
Mesh:
Substances:
Year: 2020 PMID: 33260150 PMCID: PMC7762456 DOI: 10.18632/aging.202200
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682